Gufic Biosciences Limited share price
NSE: GUFICBIO · ISIN INE742B01025
Key numbers
- Market cap
- ₹ 4,249 Cr
- Current price
- ₹ 423.75
- 52-week high / low
- ₹ 468 / 268
- Stock P/E
- 57.7
- Book value
- ₹ 66.3
- Dividend yield
- 0.02%
- ROCE
- 12.1%
- ROE
- 10.1%
- Debt to equity
- 0.61
- Sales growth (3 yrs)
- 6.1%
- Profit growth (3 yrs)
- -7.0%
- 1-year return
- 14.0%
About Gufic Biosciences Limited
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. Further, it engages in contract and bulk drug manufacturing business. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 224 | 237 | 231 | 252 | 261 |
| Operating profit | 33 | 38 | 33 | 47 | 47 |
| Net profit | 13 | 17 | 12 | 22 | 22 |
| EPS (₹) | 1.30 | 1.68 | 1.24 | 2.18 | 2.22 |
Concall summary (2026-08-21)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- So is it that maybe from next year, you will be reaching that inflection to grow beyond 20% or the business that we'll be growing at 15%, 20%.
- Basically, if you see the expected revenue from our side for '26, '27 will in the rage of around INR1100 crores.
Growth & demand
- Its launch pipeline for the year is the widest it has ever carried.
- And the 2 first mover launches are ahead, one in osteoarthritis and one addressing metabolic ovarian segment.
Margins & costs
- The EBITDA for Q1 of '25-'26 was INR33.2 crores whereas the Q1 of '26-'27 is INR47.2 crores.
- EBITDA margin in Q1 of '25-'26 was 14.6% whereas Q1 of '26-'27 is 18.09%.
Capex & expansion
- So in terms of pure capacity expansion, yes, the amount has gone from 18% to 22% last year 20% to 25% last year, then this year, close to 30%, 35%.
- So in Indore, anything around INR800 crores to a max of around INR1,200 crores, depending on the product mix, that's the maximum, I would say, capacity extraction I mean, I would say, revenue extraction possible from the current investment what we have done without any capex.
Balance sheet & cash
- For the other global markets, we have a strategy maybe post next year once we see further cash flow coming.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.